Digital dysfunction remedy

Abstract

To provide an internal medicine that can improve ill health due to digital devices.SOLUTION: A Keishi-ka-ryukotsu-borei-to extract serves as an active ingredient of an agent for improving ill health due to digital devices.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a medicine for improving digital disorders. [Background technology]

[0002] With the increasing popularity of electronic devices, working long hours at VDTs (visual display terminals) places various stresses on the mind and body of modern people, leading to digital disorders as health problems.

[0003] The cause of digital disorders is believed to be blue light (the blue component of visible light with a wavelength of approximately 380-495 nm), which is abundant in displays on electronic devices. For example, because blue light is essential for maintaining circadian rhythms, inappropriate exposure to it can lead to digital disorders through circadian rhythm disorders (Non-Patent Document 1). Therefore, the basic treatment for digital disorders is to appropriately adjust the amount and timing of blue light exposure, such as by using items with blue light blocking functions and avoiding staring at displays after sunset. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Jyusoken Research Paper Collection No. 42, 2015 edition, pp. 85-95 Summary of the Invention [Problem to be solved by the invention]

[0005] Adjusting blue light exposure is a logical approach to improving digital health, and is physically simple and easily achievable. However, modern lifestyles are inseparable from blue light exposure, making it extremely difficult to achieve ideal blue light exposure. Therefore, new methods are needed to improve digital health while still maintaining normal blue light exposure.

[0006] Therefore, the present invention aims to provide an oral medication that can improve digital disorders. [Means for solving the problem]

[0007] The present inventors have conducted extensive research and have newly discovered that Keishikaryukotsuboreito can improve digital disorders. Based on this finding, the present invention has been completed through further research.

[0008] That is, the present invention provides the following aspects. Item 1. A medicine for improving digital disorders containing Keishi Jia Longgu Muli Tang extract. Item 2. The digital disorder improving drug according to Item 1, applied to the demonstration. Item 3. A digital disorder improvement drug according to Item 1 or 2, which is applied to people who do not complain of mental health disorders. [Effects of the Invention]

[0009] According to the present invention, an oral medication capable of improving digital disorders is provided. DETAILED DESCRIPTION OF THE INVENTION

[0010] The drug for improving digital disorders of the present invention is characterized by containing Keishikaryukotsuboreito extract and being used to improve digital disorders. The drug for improving digital disorders of the present invention will be described in detail below.

[0011] Keishikaryukotsuboreito extract The Kampo prescription for Keishika Longkotsu Mulito is preferably the one described in "New Guide to General Kampo Prescriptions" (edited by Goda Yukihiro and Hakamzuka Takashi, edited by the Japan Kampo Herbal Medicine Preparation Association, published by Jiho Co., Ltd.), specifically including a mixture of herbs consisting of cinnamon bark, peony root, Chinese rhizome, scutellaria root, borehigashi, licorice root, and ginger. Furthermore, Keishika Longkotsu Mulito encompasses the mixture of herbs (Kampo prescriptions) described in currently commonly used Kampo-related letters, as stipulated in the "Basic Handling Guidelines for Kampo Preparations" established by the Kampo Herbal Medicine Research Council.

[0012] The amounts of each medicinal herb that makes up Keishi Jia Longgu Muli Tang include 1 to 4 parts by weight of cinnamon bark, preferably 1.5 to 3 parts by weight; 1 to 4 parts by weight of peony root, preferably 1.5 to 3 parts by weight; 1 to 4 parts by weight of rhizome, preferably 1.5 to 3 parts by weight; 0.75 to 3 parts by weight of rye root, preferably 1 to 2 parts by weight; 0.75 to 3 parts by weight of rye root, preferably 1 to 2 parts by weight; 0.5 to 2 parts by weight of licorice, preferably 0.75 to 1.5 parts by weight; and 0.25 to 1.5 parts by weight of ginger, preferably 0.5 to 1 part by weight.

[0013] Suitable examples of herbal medicine preparations used in the production of the Keishikaryukotsuboreito extract used in the present invention include 2 parts by weight of cinnamon bark, 2 parts by weight of peony root, 2 parts by weight of rhizome, 1.5 parts by weight of rheum rhizome, 1.5 parts by weight of borehir, 1 part by weight of licorice root, and 0.5 parts by weight of ginger.

[0014] The extract form of Keishikaryukotsuboreito may be either a liquid extract such as a soft extract, or a solid dry extract powder.

[0015] The liquid extract of Keishika Longgu Muli Tang can be obtained by extracting the mixed herbs according to the Keishika Longgu Muli Tang prescription and concentrating the resulting extract as necessary. The dried extract powder of Keishika Longgu Muli Tang can be obtained by drying the liquid extract.

[0016] In the production of an extract of Keishi Jia Longgu Muli Tang, the extraction solvent used in the extraction process is not particularly limited, and examples thereof include water or aqueous ethanol. The extraction process for Keishi Jia Longgu Muli Tang is not particularly limited, but examples include extracting the herbs contained in Keishi Jia Longgu Muli Tang with an extraction solvent in an amount approximately 5 to 10 times the total weight (dry weight equivalent) of the herbs, concentrating the extract to half its volume, and removing the solids to obtain a liquid extract of Keishi Jia Longgu Muli Tang. Furthermore, this liquid extract can be dried to obtain a dried extract powder of Keishi Jia Longgu Muli Tang. The drying process is not particularly limited, and known methods can be used, such as spray drying, or adding an appropriate adsorbent (e.g., silicic anhydride, starch, etc.) to a soft extract with an increased extract concentration to obtain an adsorbed powder.

[0017] When an extract is used as Keishika Longgu Muli Tang in the present invention, the extract prepared by the above-mentioned method may be used, or a commercially available product may be used. For example, as a dried extract powder of Keishika Longgu Muli Tang, Keishika Longgu Muli Tang Dried Extract-F (manufactured by Alps Pharmaceutical Industry Co., Ltd.) is known as a commercial product and can be obtained commercially.

[0018] In the digital disorder improving drug of the present invention, the content of Keishi Jia Longgu Muli Tang extract is not particularly limited as long as the effects of the present invention are achieved, but is typically 5 to 100 wt%, preferably 10 to 90 wt%, more preferably 20 to 80 wt%, and even more preferably 30 to 60 wt% in terms of the amount of dried extract powder of Keishi Jia Longgu Muli Tang extract. In the present invention, the amount of dried extract powder of Keishi Jia Longgu Muli Tang refers to the amount of the dried extract powder itself when Keishi Jia Longgu Muli Tang is used, and refers to the amount remaining after removing the solvent when a liquid extract of Keishi Jia Longgu Muli Tang is used. Furthermore, if the dried extract powder of Keishi Jia Longgu Muli Tang contains additives such as adsorbents added during production, the amount refers to the amount excluding these additives.

[0019] Other ingredients The digital disorder improving drug of the present invention may consist solely of Keishi-ka-ryukotsu-boreito extract, or may contain additives and bases appropriate for the formulation. Such additives and bases are not particularly limited as long as they are pharmaceutically acceptable, and examples thereof include excipients, binders, disintegrants, lubricants, isotonicity agents, plasticizers, dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, suspending agents, adhesives, coating agents, glossing agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV protection agents, preservatives, flavoring agents, fragrances, powders, thickeners, pigments, and chelating agents. These additives may be used alone or in combination of two or more. The content of these additives and bases is appropriately determined depending on the type of additives and bases used, the formulation of the digital disorder improving drug, and other factors.

[0020] In addition, the digital disorder improving drug of the present invention may contain, as necessary, other nutritional components or pharmacological components in addition to the Keishi Jia Longguo Muli Tang extract. Such nutritional components and pharmacological components are not particularly limited as long as they are pharmaceutically acceptable, and examples thereof include antacids, stomachic agents, digestive aids, intestinal regulators, antispasmodics, mucosal repair agents, anti-inflammatory agents, astringents, antiemetics, antitussives, expectorants, anti-inflammatory enzymes, sedatives, hypnotics, antihistamines, caffeine, cardiac diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, herbal extracts, vitamins, and menthols. These nutritional components and pharmacological components may be used alone or in combination of two or more. The content of these components may be appropriately determined depending on the type of components used and the formulation of the digital disorder improving drug.

[0021] Formulation The formulation of the digital disorder improving drug of the present invention is not particularly limited as long as it can be administered orally, and examples thereof include solid formulations such as powders, fine granules, granules (including dry syrup), tablets, pills, capsules (soft capsules, hard capsules), etc.; semi-solid formulations such as jellies; and liquid formulations such as solutions, suspensions, syrups, etc. Among these formulations, solid formulations are preferred from the viewpoints of the stability and portability of the contained ingredients.

[0022] To prepare the digital disorder improving drug of the present invention in the above-mentioned formulation form, the drug may be formulated using Keishikaryokutsuboreito extract, and additives, bases, and pharmacological ingredients added as needed, according to the usual formulation methods used in the pharmaceutical field.

[0023] Purpose The drug for improving digital disorders of the present invention is used for the purpose of improving digital disorders. Digital disorders refer to mental and physical disorders caused by exposure to blue light. For example, blue light exposure that can cause digital disorders can be caused by exposure to blue light at an intensity exceeding the solar radiation intensity and / or for a period exceeding the duration of sunlight. Specific examples of causes of digital disorders include work using a personal computer, smartphone, electronic tablet, etc., and work that involves staring at the display of an electronic device, such as playing games. Furthermore, the duration of such work can be, for example, 4 hours or more per day, at which point the number of subjective symptoms of digital disorders increases, and preferably 6 hours or more, at which the proportion of digital disorders other than eye strain increases. Furthermore, the time period during which such work is performed is not particularly limited, but preferably includes times including sunset.

[0024] In this way, the digital disorder ameliorating agent of the present invention is used for purposes unrelated to mental health disorders caused by psychological factors (such as poor interpersonal relationships, poor financial circumstances, difficulty in achieving goals, pressure to achieve goals, lack of ability, and psychological burdens due to various types of harassment). Therefore, the digital disorder ameliorating agent of the present invention is preferably applied to people who do not complain of mental health disorders.

[0025] Specific symptoms of digital illness include the stress caused to the mind and body by exposure to blue light, such as tired, watery or flickering eyes (eye strain); headaches; irritability; an alert brain that makes it difficult to sleep; a restless mind; tension in the head; hypertension in the nerves (body); and accumulated stress.

[0026] Furthermore, the digital disorder improving agent of the present invention is particularly preferably applied to physically strong working people who are prone to digital disorders at work. In other words, the digital disorder improving agent of the present invention is particularly preferably applied to those with a "demonstrative" condition. Here, "demonstrative" refers to one of the following conditions, which are commonly used by those skilled in the art in the field of traditional Chinese medicine when assessing physical strength: a "deficient condition" (referring to a constitution with a weak stomach and a tendency to tire easily, specific conditions including pale complexion, thinness or water weight gain, low blood pressure, and fatigue easily), an "intermediate condition" (referring to a constitution between "deficient condition" and "demonstrative" and specific conditions including moderate physical strength or slight weakness), or a "demonstrative" condition (referring to a constitution with a relatively sturdy physique, good nutrition, and a tendency to have a strong digestive system, specific conditions including good blood circulation, muscular build, a good appetite, and resistance to fatigue).

[0027] Dosage / Usage The digital disorder improving drug of the present invention is administered orally. The dosage of the digital disorder improving drug of the present invention is appropriately determined depending on the age, sex, constitution, severity of symptoms, etc. of the recipient. For example, the amount per person per day is about 0.2 to 20 g, preferably about 0.5 to 10 g, more preferably about 1 to 5 g, and even more preferably about 2 to 3 g, calculated as the dried extract powder of Keishi Jia Longguo Muli Tang extract, and is administered 1 to 3 times a day, preferably 2 or 3 times a day. The timing of administration is not particularly limited and may be before, after, or between meals, but before meals (30 minutes before a meal) or between meals (2 hours after a meal) is preferred.

[0028] The digital disorder improving drug of the present invention is excellent in improving digital disorders, and can provide an improving effect even after about 5 to 10 days. Therefore, the period of administration of the digital disorder improving drug of the present invention can be, for example, 5 days or more, 6 days or more, 7 days or more, 8 days or more, or 9 days or more, and the upper limit of the administration period can be, for example, 4 weeks or less, preferably 3 weeks or less, more preferably 2 weeks or less, and even more preferably 10 days or less, 9 days or less, 8 days or less, 7 days or less, or 6 days or less. [Example]

[0029] The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

[0030] Manufacturing of Keishikaryukotsuboreito extract powder The raw herbs were used in the following proportions: 2 parts by weight of cinnamon bark, 2 parts by weight of peony root, 2 parts by weight of Chinese cabbage, 1.5 parts by weight of rhododendron amurense, 1.5 parts by weight of mulberry root, 1 part by weight of licorice root, and 0.5 parts by weight of ginger. After chopping, these were extracted with 20 times their weight (210 parts by weight) of water at approximately 100°C for 1 hour, centrifuged to obtain an extract, which was concentrated under reduced pressure and dried using a spray dryer to obtain Keishikaryukotsuboreito extract powder. The resulting Keishikaryukotsuboreito extract powder weighed 25g per 105g of raw herbal mixture. The spray dryer drying was performed by dropping the extract into an atomizer rotating at 10,000 rpm and supplying hot air at 150°C.

[0031] Test Example The subjects were 10 healthy men and women (with no complaints of mental health problems). These subjects reported that due to the nature of their jobs, they spend long hours (more than six hours a day) staring at the displays of electronic devices such as computers, and that they suffered from particularly severe digital discomfort such as eye strain, headaches, and irritability on weekdays.

[0032] The day before the exam, participants were given an English paper to transcribe, and on the day of the exam, when they opened their computers (approximately 2.5 hours after waking up), they were asked to transcribe the paper using Word software for 15 minutes by typing. Immediately after this, saliva was collected for measuring cortisol (a stress marker). On the day of the exam, participants performed their usual office work (work) by staring at the display of an electronic device such as a computer. After completing the office work, they again transcribed and typed the English paper for 15 minutes, and saliva was collected immediately after this. This test was conducted before taking Keishikaryukotsuboreito extract, and 5 and 10 days after starting to take it. Keishikaryukotsuboreito extract was taken before or between meals, at a dose of 2.3 g (equivalent to dry extract) per day, divided into two doses per day.

[0033] Cortisol in the collected saliva was measured by ELISA. Since cortisol levels in the human body are generally higher in the morning and lower at night, the relative amount (%) of evening cortisol levels was calculated and averaged, assuming morning cortisol levels to be 100%.

[0034] As a result, the average relative cortisol level was 69% before taking the medicine (this value was elevated compared to measurements taken on a day off when no office work was performed), 44% five days after starting the medicine, and 44% ten days after starting the medicine. This shows that taking Keishi Jia Long Kotsu Muli Tang extract can improve the stress caused by office work. In fact, even though the subjects were performing their usual office work (job), they reported that the digital discomfort they had experienced before taking the medicine, such as eye strain, headaches, and irritability, had been alleviated.

[0035] Furthermore, some of the test subjects had physical strength equivalent to that demonstrated in traditional Chinese medicine, and in these individuals, the degree of reduction in relative cortisol levels was greater, and these individuals actually reported that digital discomforts such as eye strain, headaches, and irritability were alleviated.

Claims

1. A digital disorder relief drug containing Keishi Jia Longguo Muli Tang extract, which is used for clinical trials to relieve eye strain, headaches, or irritability caused by exposure to blue light.

2. The digital disorder improvement drug according to claim 1, which is applied to people who do not complain of mental health disorders.